A Prospective, Multi-center, Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects With Upper Facial Lines (Glabellar Lines, Lateral Canthal Lines, and Forehead Lines)
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles; Glabellar lines
- Focus Therapeutic Use
- Acronyms UFL BOND 974
- Sponsors AbbVie
Most Recent Events
- 10 Jan 2025 Status changed from active, no longer recruiting to completed.
- 23 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 28 Mar 2024 Planned End Date changed from 2 May 2025 to 26 Apr 2025.